P06.20 EGFRvIII: a predictive marker for Temozolomide response in O6-methylguanine-DNA methyltransferase negative glioblastoma cells and tumor xenografts

Glioblastoma multiforme (GBM) is the most common malignant brain tumor in adults with an estimated 5-year survival of less 10%. The current standard of care involves maximal tumor resection followed by radiation and chemotherapy with the alkylating agent temozolomide (TMZ). Epigenetic silencing of t...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Neuro Oncol
Asıl Yazarlar: Struve, N., Brend, T., Ott, L., Petersen, C., Rothkamm, K., Short, S. C., Kriegs, M.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Oxford University Press 2016
Konular:
P06 Biomarkers
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5782608/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/now188.111
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller